- 02:32 PM PM talks growth, reforms; outlines stimulus exit p...
- 10:28 AM Financial stability, climate change top on EU Prez...
- 10:27 AM UK joins G20 push for world levy on banks
- 10:27 AM Britain urges divided G20 to reach climate finance...
- 10:27 AM G20 leaders meet, talk about climate change, world...
- 06:47 PM 'The Sensex will test 14500 at some point…'
- 04:16 PM See scope for more int'l listings of Indian cos: N...
- 04:12 PM Dollar weakness will boost EMs, commodities ahead:...
- 04:07 PM 'India would've grown at 7% had monsoon not played...
- 03:04 PM Bye-bye Circular 23!
Broking house, P-Sec is bullish on Ranbaxy Laboratories and has recommended buy rating on the stock with a target of Rs 428.
P-Sec report on Ranbaxy Laboratories:
"Ranbaxy has received USFDA approval to manufacture and market cefprozil indicated for the treatment of infections caused by tonsillitis, acute sinusitis, bacterial infections and skin-structure infections. Cefprozil has been determined to be bioequivalent and having same therapeutic effect as that of brand Cefzil of Bristol Myers and the estimated annual market size is USD 76.6 mln."
"The company expects to launch the formulation early 2007. At CMP of Rs.370, the stock is trading at 24x CY06E and 20x CY07E earnings. Recent correction has made the valuations attractive, we maintain buy on the stock for a target price of Rs 428."
|
Stock Advice
|
|
|
Today's Special Column
with Kishore Biyani
Future Group and the MD of Pantaloon Retail (India) Limited , Group CEO
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- 10 companies that MF managers love
- 'The Sensex will test 14500 at some point…'
- Exit Suzlon Energy at Rs 83: Joshi
- Mahindra Satyam restarts hirings, recalls bench
- 'Bullish' Mark Mobius unfazed by recent market correction
- Sensex ends week 262 pts up, sectors to look at ahead
- SBI cuts deposit rates on slow credit, liquidity glut
- PM talks growth, reforms; outlines stimulus exit plan
Source: Moneycontrol.com
- 'The Sensex will test 14500 at some point…'
Source: CNBC-TV18
- See scope for more int'l listings of Indian cos: NYSE
Source: CNBC-TV18
- Dollar weakness will boost EMs, commodities ahead: HSBC
Source: CNBC-TV18
- SBI cuts deposit rates on slow credit, liquidity glut
Source: Business Line
- Aurobindo drug gets US nod
Source: Business Line
- BEML bags Rs 185 cr NCL order
Source: Business Line
- Tatas going global with low-cost housing
Source: Business Line
